Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560


Company Overview

Webcast ImageWebcast
Q3 2014 Pacira Pharmaceuticals, Inc. Earnings Conference Call  (Live)
10/30/14 at 9:00 a.m. ET
Q3 2014 Pacira Pharmaceuticals, Inc. Earnings Conference Call
Thursday, October 30, 2014 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.45 (0.45%)
Data as of 10/22/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
10/15/14Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 15, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2014, will be released before the market opens on Thursday, October 30, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, October 30, 2014, at 9 a.m. ET. The call... 
Printer Friendly Version
10/13/14Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety of EXPAREL® in Peripheral Nerve Block
-- Analysis Presented at the 2014 Annual Meeting of the American Society of Anesthesiologists Finds the Safety of EXPAREL Similar to Placebo and Bupivacaine HCl -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 13, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data demonstrating that EXPAREL® (bupivacaine liposome injectable suspension) used in peripheral nerve blocks has comparable safety to placebo and bupivacaine HCl. T... 
Printer Friendly Version
09/25/14Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter
PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Warning Letter (attached for reference) from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) referencing certain promotional materials on EXPAREL® (bupivacaine liposome injectable suspension). “We take regulatory compliance very seriously and believe that our ... 
Printer Friendly Version
08/05/14Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014, at 8:35 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the ... 
Printer Friendly Version

Corporate Presentation

Corporate Presentation
Upcoming EventsMore >>
10/30/14 9:00 a.m. ET
Q3 2014 Pacira Pharmaceuticals, Inc. Earnings Conference Call
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Jessica Cho
(973) 254-3574